Data from the ONWARDS clinical trial program supported the efficacy of once-weekly insulin icodec-abae compared with daily basal insulin. The Food and Drug Administration (FDA) has approved Awiqli ® ...

Compared with once-daily comparators, once-weekly icodec was associated with similar safety and efficacy outcomes regardless of race, ethnicity, or age. The hypoglycemic profile and efficacy of ...

Insulin icodec-abae (Awiqli; Novo Nordisk) is now approved for use in the US, Canada, European Union, Switzerland, and 12 other countries. Its indication is as an adjunct to diet and exercise for ...

On Sunday in Chicago, Dr. Athena Philis-Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute in La Jolla, helped deliver positive news for the estimated 7 million Americans who ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Insulin efsitora was noninferior to once-daily insulins ...

Life with diabetes usually includes many injections of the blood sugar–controlling hormone insulin. Recent research investigating a once-weekly shot finds it might help lessen the burden a bit for ...